FOLH1 and cancer: The reason for the low sensitivity was that the binding site of [111In]-capromab pendetide is located on the intracellular domain of PSMA; hence, a positive imaging result using this agent could also be due to the presence of dead/dying cells in the cancer tissue [52,53].